Yueyin Pan

10.2k total citations
130 papers, 2.3k citations indexed

About

Yueyin Pan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Yueyin Pan has authored 130 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 72 papers in Oncology, 53 papers in Pulmonary and Respiratory Medicine and 42 papers in Molecular Biology. Recurrent topics in Yueyin Pan's work include Lung Cancer Treatments and Mutations (27 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Lung Cancer Research Studies (15 papers). Yueyin Pan is often cited by papers focused on Lung Cancer Treatments and Mutations (27 papers), Cancer Immunotherapy and Biomarkers (16 papers) and Lung Cancer Research Studies (15 papers). Yueyin Pan collaborates with scholars based in China, United States and United Kingdom. Yueyin Pan's co-authors include Hu Liu, Kangsheng Gu, Xinghua Han, Fuxing Xiong, Zhendong Chen, Geng Song, Hossam Haick, Qingling Hua, Tao Qin and Guobing Xu and has published in prestigious journals such as Science, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Yueyin Pan

117 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yueyin Pan China 26 747 735 641 620 384 130 2.3k
Kangsheng Gu China 22 661 0.9× 521 0.7× 288 0.4× 480 0.8× 335 0.9× 119 1.8k
Xudong Zhu China 27 620 0.8× 1.0k 1.4× 377 0.6× 405 0.7× 368 1.0× 125 2.3k
Ting Xu China 31 1.2k 1.6× 968 1.3× 683 1.1× 971 1.6× 472 1.2× 175 3.6k
Tomasz Stokłosa Poland 25 375 0.5× 915 1.2× 384 0.6× 462 0.7× 310 0.8× 100 2.3k
Yue Jin China 32 529 0.7× 1.5k 2.0× 349 0.5× 268 0.4× 737 1.9× 90 2.7k
Shawn E. Lupold United States 26 798 1.1× 2.6k 3.5× 421 0.7× 696 1.1× 1.1k 2.8× 58 3.9k
Shiwei Guo China 24 524 0.7× 571 0.8× 313 0.5× 168 0.3× 286 0.7× 89 1.5k
Yuying Tan United States 35 548 0.7× 1.1k 1.5× 638 1.0× 329 0.5× 762 2.0× 95 3.2k
Peipei Xu China 24 339 0.5× 800 1.1× 576 0.9× 315 0.5× 261 0.7× 159 2.2k

Countries citing papers authored by Yueyin Pan

Since Specialization
Citations

This map shows the geographic impact of Yueyin Pan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yueyin Pan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yueyin Pan more than expected).

Fields of papers citing papers by Yueyin Pan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yueyin Pan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yueyin Pan. The network helps show where Yueyin Pan may publish in the future.

Co-authorship network of co-authors of Yueyin Pan

This figure shows the co-authorship network connecting the top 25 collaborators of Yueyin Pan. A scholar is included among the top collaborators of Yueyin Pan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yueyin Pan. Yueyin Pan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pan, Yueyin, et al.. (2025). A novel serum protein biomarker for the late-stage diagnosis of nasopharyngeal carcinoma. BMC Cancer. 25(1). 585–585. 1 indexed citations
2.
Wan, Mengting, Benjie Shan, Hongwei Jin, et al.. (2025). Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment. Molecular Cancer. 24(1). 61–61. 18 indexed citations
3.
Yu, Haiyang, Xin Sun, Yan Li, et al.. (2025). Macrophage NLRP3 activation and IL-1β release drive osimertinib-induced antitumor immunity. Journal for ImmunoTherapy of Cancer. 13(10). e012182–e012182. 1 indexed citations
4.
5.
Xu, Mengran, Fujun Lai, Danping Hu, et al.. (2024). A nanozyme-based drug delivery system to amplify ferroptosis via MET inhibition and photodynamic therapy. Chemical Engineering Journal. 500. 156920–156920. 6 indexed citations
6.
Wang, Tingting, Jinnan Wang, Wei Zhao, & Yueyin Pan. (2024). Clinical Outcomes and Intrinsic Subtypes of Breast Cancer Patients with Single Hormone Receptor-positive Receiving Neoadjuvant Chemotherapy. Clinical Breast Cancer. 24(5). e370–e378.e1. 3 indexed citations
7.
Jing, Lin, Hui Wang, Weizhen Zhang, et al.. (2024). First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with advanced melanoma: Safety and efficacy results from a phase I study.. Journal of Clinical Oncology. 42(16_suppl). 9562–9562. 3 indexed citations
8.
Li, Yan, Chao Xu, Xiaojun Qian, et al.. (2024). Myeloid PTEN loss affects the therapeutic response by promoting stress granule assembly and impairing phagocytosis by macrophages in breast cancer. Cell Death Discovery. 10(1). 344–344. 2 indexed citations
9.
Zhou, Shoubing, et al.. (2024). Synergistic approach to combating triple-negative breast cancer: DDR1-targeted antibody-drug conjugate combined with pembrolizumab. Journal of Pharmaceutical Analysis. 15(5). 101100–101100. 3 indexed citations
10.
Gao, Hongfei, Min Yan, Qianjun Chen, et al.. (2023). Effectiveness and Safety of Palbociclib Plus Endocrine Therapy in Patients with Advanced Breast Cancer: A Multi-Center Study in China. Cancers. 15(17). 4360–4360. 2 indexed citations
11.
Xu, Binghe, Fei Ma, Tao Wang, et al.. (2023). A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple‐negative breast cancer who received at least two prior treatments. International Journal of Cancer. 152(10). 2134–2144. 27 indexed citations
12.
13.
Wu, Mingming, Xiao Zhang, Weijie Zhang, et al.. (2022). Cancer stem cell regulated phenotypic plasticity protects metastasized cancer cells from ferroptosis. Nature Communications. 13(1). 1371–1371. 107 indexed citations
14.
Liu, Yu, Xinghua Han, Yueyin Pan, et al.. (2021). An Immune-Associated Genomic Signature Effectively Predicts Pathologic Complete Response to Neoadjuvant Paclitaxel and Anthracycline-Based Chemotherapy in Breast Cancer. Frontiers in Immunology. 12. 704655–704655. 7 indexed citations
15.
Wang, Juan, Shun Lü, Yehuan Sun, et al.. (2021). OA03.04 Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 16(1). S3–S3. 1 indexed citations
16.
Xing, Ligang, Yueyin Pan, Yuankai Shi, et al.. (2020). Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study. Clinical Cancer Research. 26(23). 6168–6175. 28 indexed citations
17.
18.
19.
Du, Yingying, et al.. (2012). Synergistic Effects of Exemestane and Aspirin on MCF-7 Human Breast Cancer Cells. Asian Pacific Journal of Cancer Prevention. 13(11). 5903–5908. 18 indexed citations
20.
Pan, Yueyin, et al.. (1995). Short-time effects of bronchial artery infusion with chemical drugs for lung cancer. Chinese Journal of Cancer Research. 7(2). 153–156.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kangsheng Gu Breakdown of academic impact, for papers by Xudong Zhu Breakdown of academic impact, for papers by Ting Xu Breakdown of academic impact, for papers by Tomasz Stokłosa Breakdown of academic impact, for papers by Yue Jin Breakdown of academic impact, for papers by Shawn E. Lupold Breakdown of academic impact, for papers by Shiwei Guo Breakdown of academic impact, for papers by Yuying Tan Breakdown of academic impact, for papers by Peipei Xu
Rankless by CCL
2026